Our results suggest that GDNF ameliorated the defect of DAT glycosylation modification to increase its membrane distribution by enhancing Golgi aggregation, followed by the enhancement of DA signaling, and ultimately ameliorating cognitive impairment in PD. This evidence concerns the gene SLC6A3 and Parkinson disease.